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a  b  s  t  r  a  c  t
Hyperammonemia  is  associated  with  chronic  and  acute  liver  injury.  There  is  no  promising  therapeutic
agent  against  ammonia-induced  complications.  Hence,  ﬁnding  therapeutic  molecules  with  safe  proﬁle
of administration  has  clinical  value.  The  present  study  was  conducted  to  evaluate  the  role  of  taurine  (TA)
administration  on plasma  and  brain  ammonia  and  its consequent  events  in different  models  of chronic
and  acute  liver  injury  and  hyperammonemia.  Bile  duct  ligated  (BDL)  rats  were  used as  a model  of chronic
liver  injury.  Thioacetamide  and  acetaminophen-induced  acute  liver  failure  were  used  as  acute  liver  injury
models.  A  high  level  of ammonia  was  detected  in blood  and  brain  of  experimental  groups.  An  increase
in  brain  ammonia  level  coincided  with a decreased  total  locomotor  activity  of  animals  and signiﬁcant
changes  in the  biochemistry  of blood  and  also liver  tissue.  TA  administration  (500  and  1000  mg/kg,  i.p),
effectively  alleviated  liver injury  and  its consequent  events  including  rise in plasma  and  brain  ammonia
and  brain  edema.  The  data suggested  that  TA  is not  only  a useful  and  safe agent  to  preserve  liver  function,
but  also  prevented  hyperammonemia  as  a deleterious  consequence  of acute  and  chronic  liver  injury.
©  2016  Published  by  Elsevier  Ireland  Ltd.  This is an  open  access  article  under the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).eywords:
mino acid
mmonia
rain edema
epatic encephalopathy
epatic injury
epatoprotective
. Introduction
Taurine (TA; -amino sulfonic acid) is one of the most abundant
mino acids in the human body [1]. TA is present in our daily foods
nd dietary supplements. A broad range of pharmacological and
hysiological effects are attributed to this amino acid [2–5]. It has
∗ Corresponding author at: Akram Jamshidzadeh, Pharmacology and Toxicology
epartment, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
E-mail address: ajamshid@sums.ac.ir (A. Jamshidzadeh).
ttp://dx.doi.org/10.1016/j.toxrep.2016.04.002
214-7500/© 2016 Published by Elsevier Ireland Ltd. This is an open access article under been reported that the hepatic TA level has been decreased in some
liver disease and/or xenobiotics-induced hepatic injury [6]. TA con-
centration in plasma and urine is also reported as a biomarker of
hepatic injury because of its release from pre-central hepatocytes
[6,7]. On the other hand, it has been shown that TA plays a protec-
tive role against many xenobiotics [8–15]. Therefore, these results
show that TA serves as a hepatoprotective agent to prevent liver
injury [16]. TA also has been shown to have a profound effect in cen-
tral nervous system (CNS) [17,18]. It has been shown that TA acts as
an osmoregulator, protects neurons, prevents astrocytes swelling
and encounters oxidative stress in CNS [19–22].
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hepatic encephalopathy (HE) is a serious complication associ-
ted with liver cirrhosis and/or acute liver failure [23]. Although the
athophysiology of HE is not fully understood, there is agreement
n the importance of neurotoxins, especially ammonia [24]. Liver
s the main organ responsible for ammonia detoxiﬁcation via the
rea cycle [25]. Hence, any defect in liver function and urea cycle
ight lead to hyperammonemia and conclusively HE. Ammonia is
 neurotoxin which triggers a variety of neurological complications
24]. Ammonia causes oxidative stress and brain edema [24,26,27],
nduces neuroinﬂammation [28–30], and affects vital organelles
uch as mitochondria [24,31].
Although the hepatic/neuroprotective properties of TA are well
stablished, the effects of this amino acid on blood and brain ammo-
ia, as a key factor in the consequences of acute and/or chronic
iver injury and HE, has not been investigated so far. In the present
tudy, we proposed to examine the effects of TA on hepatic injury,
lasma and brain ammonia as well as brain damage in different
xperimental models of chronic and acute liver failure.
. Material and methods
.1. Chemicals
Taurine (2-amino-ethane sulfonic acid) was obtained from
cros (New Jersey, USA). Acetaminophen, thioacetamide,
richloroacetic acid (TCA), 5,5′-dithionitrobenzoic acid (DTNB),
hiobarbituric acid (TBA), sodium citrate, sodium hypochlo-
ite solution (5%), ammonium chloride, nicotinamide adenine
inucleotide phosphate (NADPH), phenol, sodium nitroprus-
ide dihydrate, ethylenediamine tetra-acetic acid (EDTA),
-nitrophenol, phosphoric acid, 2-amino-2-hydroxymethyl-
ropane-1,3-diol-hydrochloride (Tris–HCl), were obtained from
erck (Darmstadt, Germany). Kits for evaluating biomarkers of
iver injury, including ALT, LDH, AST, ALP and bilirubin, were
btained from Pars Azmun® (Tehran, Iran). All salts used for
reparing buffer solutions were of analytical grade and obtained
rom Merck (Darmstadt, Germany).
.2. Animals
Male Sprague-Dawley rats (n = 54; 200–300 g weight) and male
wiss albino mice, (n = 30; 20–35 g weight) were obtained from the
enter for Comparative and Experimental Medicine, Shiraz Univer-
ity of Medical Sciences, Shiraz, Iran. Animals were housed in plastic
ages over hardwood bedding. There was an environmental tem-
erature of 24 ◦C and a 12L: 12D photoschedule along with a 40%
f relative humidity. The rats were allowed ad-libitum access to a
ormal standard chow diet and water. Animals received humane
are and all the experiments were performed in conformity with
he guidance for care and use of experimental animals approved
y a local ethic committee in Shiraz University of Medical Sciences,
hiraz, Iran (#93-01-36-7609).
.3. Experimental setup
.3.1. Bile duct ligation (BDL) in rat as a model for chronic liver
njury and cirrhosis
Bile duct ligation (BDL) in rats is a very reproducible bil-
ary cirrhosis animal model with all complications of hepatic
ncephalopathy including a rise in blood ammonia and its
ssociated neurobiological disorders [32]. Animals (n = 24) were
nesthetized (10 mg/kg of xylazine and 70 mg/kg of ketamine, i.p), midline incision was made and the common bile duct was  local-
zed, doubly ligated, and cut between these two  ligatures [33]. The
ham operation consisted of laparotomy and bile duct identiﬁcation
nd manipulation without ligation. Animals received TA (500 andports 3 (2016) 870–879 871
1000 mg/kg live weight/day, i.p) for 28 consecutive days. On day
29 after the BDL operation, rats were anesthetized with thiopental
(80 mg/kg, i.p) and liver, brain and blood samples were collected for
further studies [33,34]. Sham-operated (control) animals received
TA vehicle (normal saline).
2.3.2. Thioacetamide-induced acute liver injury in rats
Thioacetamide is extensively used as a model of acute hep-
atic failure [35]. Thioacetamide-induced fulminant hepatic failure
was achieved by three consecutive i.p injections of thioacetamide
(400 mg/kg) to rats (n = 30) at 24-h intervals [36]. TA (500 and
1000 mg/kg, i.p) was  administered for three consecutive days, two
hours after each dose of thioacetamide. On the fourth day (24 h
after the last dose of thioacetamide), animals were anesthetized
(thiopental, 80 mg/kg, i.p) and their blood, brain, and liver were col-
lected. Supportive therapy by administering 5% dextrose (25 mL/kg
body weight, S.C) containing 0.45% sodium chloride and 0.2% potas-
sium chloride, was given to avoid weight loss, hypoglycemia and
renal failure [36]. Control animals (Vehicle-treated) received nor-
mal  saline as the thioacetamide solvent. The sole TA (1000 mg/kg,
i.p) was  administered to ensure its safety.
2.3.3. Acetaminophen-Induced acute liver injury in mice
Acetaminophen (paracetamol) (APAP) is a commonly used
drug which can produce hepatic damage. Mice are more sus-
ceptible to acetaminophen hepatotoxicity than rats [37]. A high
dose of acetaminophen (1 g/kg, i.p) was  administered to mice
(n = 30) and liver injury was  assessed 24 h after drug administra-
tion [38]. TA (500 and 1000 mg/kg, i.p) was administered two  hours
after acetaminophen. Control animals received acetaminophen sol-
vent (Dimethyl sulfoxide, 0.1 mL). A group of mice received TA
(1000 mg/kg, i.p) alone.
2.4. Plasma biochemistry and tissue histopathology
A MindrayBS-200® auto analyzer and standard kits (Pars
Azmun®) were used to measure plasma alanine aminotransferase
(ALT), aspartate aminotransferase (AST), lactate dehydrogenase
(LDH), alkaline phosphatase (ALP), and bilirubin [39]. Plasma
ammonia was  measured with standard commercial kits with a
method based on Bertholet phenate-hypochlorate reaction [40].
For histopathological assessments, samples of liver were ﬁxed in
buffered formalin solution (0.4% sodium phosphate monobasic,
NaH2PO4, 0.64% sodium phosphate dibasic, Na2HPO4, and 10%
formaldehyde in distilled water). Parafﬁn-embedded sections of
tissue (5 m)  were prepared and stained with hematoxylin and
eosin (H&E) before light microscope viewing. Liver ﬁbrotic changes
were determined by Masson’s trichrome staining in BDL rats. The
Ishak system which uses a six-point scale for ﬁbrosis stage (0–6)
was applied for scoring liver ﬁbrosis in BDL rats [41,42].
2.5. Brain ammonia level
Samples (100 mg)  of the forebrain (cerebral cortex) were dis-
sected, homogenized, and deproteinized in 3 mL  of ice-cooled lysis
solution containing trichloroacetic acid (6%, w/v). After centrifuga-
tion at 12,000g for 10 min  at 4 ◦C, the supernatants were collected
and neutralized with 2 mol/l KHCO3 (pH = 7). Brain ammonia con-
tent was  measured using standard kits, based on the absorbance
photometry method of phenate-hypochlorate reaction [40].
2.6. The open ﬁeld test for locomotors activity assessmentOpen ﬁeld behavior is used as an index of animals’ locomotor
activity in the animal models of hyperammonemia and hepatic
encephalopathy [43,44]. The open ﬁeld test was conducted for each
8 ogy Reports 3 (2016) 870–879
g
p
L
2
ﬂ
T
G
a
u
l
2
m
a
t
w
a
2
c
a
(
4
b
a
a
2
s
s
o
(
w
w
v
t
5
2
a
i
E
t
(
c
u
c
m
1
a
n
t
m
T
a
1
p
ss
es
se
d
 
in
 
d
if
fe
re
n
t 
m
od
el
s 
of
 
ch
ro
n
ic
 
an
d
 
ac
u
te
 
li
ve
r 
in
ju
ry
 
an
d
 
th
e 
ro
le
 
of
 
ta
u
ri
n
e 
ad
m
in
is
tr
at
io
n
.
Pl
as
m
a
A
LT
(U
/l
)
Pl
as
m
a 
A
ST
(U
/l
)
Pl
as
m
a
LD
H
(U
/l
)
Pl
as
m
a
A
LP
(U
/l
)
Pl
as
m
a
B
il
ir
u
bi
n
(m
g/
d
l)
Pl
as
m
a
am
m
on
ia
(
g/
d
l)
Li
ve
r
G
SH
(
m
ol
/m
g
ti
ss
u
e)
Li
ve
r
TB
A
R
S
(n
m
ol
/m
g
ti
ss
u
e)
B
ra
in
 
ed
em
a
(%
 
br
ai
n
 
w
at
er
)
Su
rv
iv
al
R
at
e 
(%
)
h
ic
le
-t
re
at
ed
 
ra
t)
 
45
 
± 
3 
84
 
± 
9 
31
6 
± 
68
 
57
1 
± 
86
 
0.
09
 
± 
0.
01
 
22
3 
± 
22
 
67
.8
6 
± 
9.
35
 
1.
87
 
± 
0.
22
 
81
 
± 
3 
10
0
h
ic
le
-t
re
at
ed
 
m
ic
e)
17
 
±  
5
48
 
±  
7
16
4  
±  
42
45
6 
±  
10
6
0.
03
 
±  
0.
01
24
1 
±  
36
75
.8
0  
±  
10
.5
0
1.
86
 
±  
0.
23
79
 
±  
4 
10
0
at
ed
 
ra
ts
 
(1
00
0 
m
g/
kg
) 
33
 
± 
7 
72
 
± 
9 
28
4 
± 
57
 
39
6 
± 
12
3 
0.
08
 
± 
0.
03
 
18
6 
± 
53
 
82
.5
3 
± 
7.
45
 
1.
04
 
± 
0.
51
 
78
 
± 
5 
10
0
at
ed
 
m
ic
e  
(1
00
0  
m
g/
kg
)
22
 
±  
6
53
 
±  
8
20
9  
±  
18
28
6 
±  
98
0.
07
 
±  
0.
03
 
30
4  
± 
56
 
84
.3
1 
± 
4.
29
 
1.
23
 
± 
0.
61
 
82
 
± 
4 
10
0
ed
 
ra
ts
 
75
1 
± 
10
8
*
15
83
 
± 
36
6*
31
51
 
± 
26
9*
75
5 
± 
99
 
0.
36
 
± 
0.
04
*
62
5 
± 
39
*
14
.2
5 
± 
2.
30
*
9.
57
 
± 
1.
57
*
87
 
± 
1 
10
0
ga
te
d
 
(B
D
L)
 
ra
ts
d
33
5 
± 
38
*
23
7 
± 
55
*
60
6 
± 
72
*
17
38
 
± 
37
0*
12
.5
3 
± 
0.
45
*
93
8 
± 
70
*
26
.4
7 
± 
3.
95
*
3.
93
 
± 
1.
10
*
92
 
± 
2*
66
.6
6*
ed
 
m
ic
ed
53
6  
±  
13
0*
62
7  
±  
10
2*
10
83
 
±  
27
9*
56
9  
±  
65
0.
22
 
±  
0.
02
*
11
10
 
±  
42
*
29
.9
0  
±  
3.
70
*
10
.8
5  
±  
0.
7*
93
 
±  
3*
66
.6
6*
n
e 
50
0 
m
g/
kg
 
13
1 
± 
29
a
47
6 
± 
11
7
a
89
0 
± 
58
a
68
0 
± 
75
 
0.
20
 
± 
0.
03
a
49
0 
± 
41
a
17
.7
5 
± 
2.
32
 
2.
44
 
± 
0.
13
a
82
 
± 
2 
10
0
n
e  
10
00
 
m
g/
kg
11
8 
±  
34
a
32
4  
±  
67
a
61
8  
±  
14
3a
59
6  
±  
12
1
0.
14
 
± 
0.
02
a
22
0 
± 
22
a
21
.2
3 
± 
1.
45
a
2.
60
 
± 
0.
40
a
83
 
± 
2 
10
0
n
e 
50
0 
m
g/
kg
 
13
9 
± 
31
b
11
4 
± 
10
b
32
1 
± 
40
b
58
3 
± 
92
b
2.
80
 
± 
0.
05
b
27
8 
± 
26
b
50
.0
0 
± 
5.
51
b
2.
60
 
± 
0.
12
b
80
 
± 
3b
10
0b
n
e 
10
00
 
m
g/
kg
 
13
4 
± 
19
b
12
8 
± 
40
b
29
5 
± 
42
b
68
1 
± 
80
b
2.
62
 
± 
0.
08
b
22
8 
± 
38
b
52
.1
 
± 
4.
28
b
2.
2 
± 
0.
23
b
78
 
± 
3b
10
0b
ri
n
e  
50
0  
m
g/
kg
98
 
±  
10
c
33
0  
±  
30
c
22
6  
±  
58
c
60
9  
±  
11
1
0.
06
 
±  
0.
01
c
79
1  
±  
63
c
50
.0
0  
±  
1.
50
c
7.
40
 
±  
0.
28
c
81
 
±  
3c
10
0
c
ri
n
e 
10
00
 
m
g/
kg
 
79
 
± 
13
c
32
2 
± 
80
c
28
0 
± 
47
c
55
1 
± 
54
 
0.
02
6 
± 
0.
01
c
70
8 
± 
52
c
53
.1
3 
± 
4.
30
c
6.
61
 
± 
0.
30
c
83
 
± 
2
c
10
0
c
n
 
as
 
M
ea
n
 
± 
SE
M
 
fo
r 
ea
ch
 
gr
ou
p
 
(n
 
= 
6)
. T
A
A
: 
Th
io
ac
et
am
id
e,
 
B
D
L:
 
B
il
e 
d
u
ct
 
li
ga
te
d
, A
PA
P:
 
A
ce
ty
l P
ar
a 
am
in
o 
p
h
en
ol
, A
ce
ta
m
in
op
h
en
.
n
iﬁ
ca
n
tl
y  
d
if
fe
re
n
t  
as
 
co
m
p
ar
ed
 
to
 
co
n
tr
ol
 
an
im
al
s  
(P
 
< 
0.
05
).
gn
iﬁ
ca
n
t 
d
if
fe
re
n
ce
 
as
 
co
m
p
ar
ed
 
to
 
th
io
ac
et
am
id
e-
tr
ea
te
d 
ra
ts
 
(P
 
< 
0.
05
).
 
si
gn
iﬁ
ca
n
t 
d
if
fe
re
n
ce
 
as
 
co
m
p
ar
ed
 
to
 
B
D
L 
ra
ts
 
(P
 
< 
0.
05
).
 
si
gn
iﬁ
ca
n
t  
d
if
fe
re
n
ce
 
as
 
co
m
p
ar
ed
 
to
 
A
PA
P-
tr
ea
te
d
 
m
ic
e 
(P
 
< 
0.
05
).
of
 
si
x 
an
im
al
s 
w
er
e 
d
ea
th
 
(n
 
= 
4)
.72 R. Heidari et al. / Toxicol
roup ﬁve hours before animal anesthesia and blood and liver sam-
le collection. The apparatus was made of white wood box (100 cm
 × 100 cm W × 30 cm H, box ﬂoor was divided into 25 squares of
0 × 20 cm for rats and 20 cm L × 30 cm W × 15 cm H, which box
oor was divided into 12 squares of equal size for mice) [45–47].
he open ﬁeld arena was equipped with a webcam (2.0-Megapixel,
igaware, UK) and all activities were monitored and recorded from
 separate room. Animals behavior was recorded for ﬁfteen min-
tes and the total number of crossed squares were counted (Total
ocomotion) [45,46].
.7. Brain edema
Brain water content was determined by the wet/dry weight
ethod. A sample of 100 mg  tissue of the cerebral cortex was  sep-
rated. First, the wet weight of brain tissue was determined. Then,
he tissue was dried overnight in an oven at 120 ◦C, and dry weights
ere determined. The difference in wet/dry weights was expressed
s percent brain water content as an index of brain edema [48].
.8. Hepatic glutathione content
Tissue samples (200 mg)  were homogenized in 8 mL  of ice-
ooled EDTA (20 mM).  Then, 5 mL  of the prepared homogenate were
dded to 4 mL  of distilled water and 1 mL  of trichloroacetic acid
50% w/v). The mixture was shaken well and centrifuged (10,000g,
◦C, 25 min). 2 mL  of the supernatant was mixed with 4 mL  of Tris
uffer (pH = 8.9), and 100 l of DTNB (0.01 M in methanol). The
bsorbance of the developed color was measured in 412 nm using
n Ultrospec 2000®UV spectrophotometer [49].
.9. Lipid peroxidation
As an index of lipid peroxidation, the thiobarbituric acid reactive
ubstances (TBARS) test was used [49]. The reaction mixture con-
ists of 500 L of tissue homogenate (10% w/v in KCl, 1.15%), 1 mL
f thiobarbituric acid (0.375%, w/v), and 3 mL  of phosphoric acid
1% w/v, pH = 2). Samples were mixed well and heated in boiling
ater (100 ◦C) for 45 min. After the incubation period, the mixture
as cooled, and then 2 mL  of n-butanol was added. Samples were
igorously vortexed and centrifuged (10,000g for 5 min). Finally,
he absorbance of developed color in n-butanol phase was read at
32 nm using an Ultrospec 2000®UV spectrophotometer [49].
.10. Cytochrome 2E1 activity assessment
Hepatic microsomes were prepared by low-speed calcium
ggregation method [50]. Brieﬂy, 1 g of liver tissue was minced
n 10 mL  of Tris–EDTA buffer (50 mM Tris–HCl, 150 mM  KCl, 2 mM
DTA, pH 7.4) and homogenized. The liver homogenate was cen-
rifuged (10 min, 10,000g, 4 ◦C) and the supernatant was  collected
crude homogenate). Then, the crude homogenate was diluted with
alcium-containing (CaCl2, 8 mM)  Tris–EDTA buffer to a ﬁnal vol-
me  of 25 mL.  After 4 min  of incubation (25 ◦C), the samples were
entrifuged (30 min, 25,000g, 4 ◦C) [50,51]. Finally, the microso-
al  pellets were suspended in a buffer containing 50 mM Tris–HCl,
0 mM KH2PO4, 0.1 mM EDTA, and 20% glycerol (pH 7.4) and stored
t −80 ◦C for later enzymatic assays.
CYP2E1 activity was measured by the rate of oxidation of p-
itrophenol to p-nitrocatechol in the presence of NADPH according
o the method of Reinke and Moyer [52]. Brieﬂy, microsomes was
ixed with a solution containing 0.2 mM p-nitrophenol, 50 mM
ris- HCl and 5 mM MgCl2 (pH = 7.4). The reaction was  performed
t 37 ◦C and was started by the addition of 1 mM NADPH. After
0 min, the reaction was stopped with 0.6 N perchloric acid. The
recipitated proteins were removed by centrifugation at 3000 g Ta
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Fig. 1. Effect of taurine administration on brain ammonia level and animals’ locomotors activity in different models of liver injury. The relationship between the locomotor
activity and the brain ammonia levels were determined by the Pearson’s regression analysis (Refer to result section for the correlation levels between groups). TAA:
Thioacetamide, BDL: Bile duct ligated, APAP: Acetyl para amino phenol, Acetaminophen. TA: Taurine.
Data are expressed as Mean ± SEM for each group (n = 6).
***Indicates signiﬁcantly different as compared to the control animals (P < 0.001).
aShows signiﬁcant difference as compared to TTA-treated group (P < 0.05).
bIndicates signiﬁcantly different as compared to BDL rats (P < 0.05).
cIndicates signiﬁcant difference as compared to APAP-treated mice (P < 0.05).
Table 2
Liver histopathological changes in different experimental groups.
Pathologic assessment
Treatment
Conﬂuent
Necrosis
Focal Necrosis Portal
Inﬂammation
Interface
Hepatitis
Ballooning
degeneration
Fatty changes Total grade Ishak stage of
liver ﬁbrosis
Control (vehicle-treated rats) 0 0 0 0 0 0 0 –
Control (vehicle-treated mice) 0 0 0 0 0 0 0 –
TAA  −treated rats 0 2 3 0 3 1 8 –
Bile  duct ligated (BDL) rats 5 2 2 2 1 0 12 5
APAP-treated mice 3 3 0 0 0 1 7 –
TAA  + Taurine 500 mg/kg 0 1 2 0 2 0 5 –
TAA  + Taurine 1000 mg/kg 0 2 1 0 1 0 4 –
BDL  + Taurine 500 mg/kg 0 0 2 2 1 0 5 3
BDL  + Taurine 1000 mg/kg 0 0 1 1 1 0 3 2
APAP+ Taurine 500 mg/kg 0 0 1 1 1 1 4 –
APAP+ Taurine 1000 mg/kg 0 0 1 1 0 1 3 –
T rosis 
p
f
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m
che Ishak system (a six-point scale for ﬁbrosis stage) was applied for scoring liver ﬁb
ara  amino phenol, Acetaminophen.
or 5 min  and the supernatants were mixed with NaOH(10 N) for
he measurement of p-nitrocatechol at 510 nm using an Ultrospec
000®UV spectrophotometer [53]. Protein content of the samples
as determined using the Bradford method [54].
.11. Statistical analysisData are given as Mean ± SEM. Comparison of data sets was  per-
ormed by the one-way analysis of variance (ANOVA) with Tukey’s
ultiple comparison as a post hoc test. Values of P < 0.05 were
onsidered statistically signiﬁcant. The relationship between thein BDL rats (Fig. 2) [41,42]. TAA: Thioacetamide, BDL: Bile duct ligated, APAP: Acetyl
locomotor activity and the brain ammonia were determined by the
Pearson’s regression analysis.
3. Results
3.1. Effect of taurine on serum biochemistry in chronic and acute
liver injuryThe effects of BDL, paracetamol and thioacetamide and differ-
ent doses of TA on the liver and plasma biochemical parameters are
summarized in Tables 1. A signiﬁcant increase in the activities of
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Fig. 2. The histological photomicrographs of the liver in bile duct ligated rats and the effect of taurine administration (See also Table 2). Representative photomicrographs
of  liver sections processed for H&E (upper row) and Masson’s trichrome (lower row) staining (200×). Scale bar, 1060 m. Sham (A&E), BDL (B&F), BDL+ Taurine 500 mg/kg
(C&G),  and BDL + Taurine 1000 mg/kg (D&H). Extensive tissue necrosis and bridging ﬁbrosis in untreated BDL rats are shown in B and F (Yellow arrow; Ishak grade 5; Table 2).
A ), G (I
c rrow
O
p
b
c
a
i
c
a
3
a
i
i
(
b
n
E
i
a
n
a
m
A
(
i
a
gll  these lesions were markedly attenuated in Taurine-treated BDL animals (C&D
hanges were observed in liver tissues with the sham operation (A) (Table 2). Red a
range: Sinusoidal Congestion. BDL: Bile duct ligated.
lasma enzyme levels (ALT, LDH, AST, and ALP), plasma total biliru-
in, hepatic lipid peroxidation and a decrease in liver glutathione
ontent were detected in thioacetamide and paracetamol-treated
nimals as well as in BDL rats (Table 1). It was found that TA admin-
stration (500 and 1000 mg/kg) signiﬁcantly alleviated pathological
hanges in plasma and liver biochemistry in all investigated acute
nd chronic models of liver injury (Table 1).
.2. Effect of taurine on brain edema, plasma and brain ammonia,
nd animals’ locomotor activity after acute and chronic liver
njury
The brain edema assessment revealed a signiﬁcant increase
n brain water in the acetaminophen-treated and BDL animals
Table 1). It was found that TA administration effectively mitigated
rain edema (Table 1). A signiﬁcant elevation in plasma ammo-
ia was observed in all investigated liver injury models (Table 1).
levation in plasma ammonia was accompanied with an increase
n brain ammonia levels and a decrease in the total locomotor
ctivity of animals (Fig. 1). Correlation analysis showed that the
umber of square crossings is negatively correlated with the brain
mmonia levels in thioacetamide and acetaminophen-treated ani-
als as well as in BDL rats (TAA-treated r = −0.823; p < 0.044;
PAP-treated r = −0.939; p < 0.0001, BDL rats r = −0.951, p < 0.0036)
Fig. 1). This negative correlation means that as plasma ammonia
ncreases, animals locomotor activity tends to decrease. Plasma
nd brain ammonia levels were signiﬁcantly lower in TA-treated
roups (Table 1 and Fig. 1). Furthermore, TA administration (500shak grade 3; Table 2) and H (Ishak grade 2; Table 2). No signiﬁcant pathological
: Conﬂuent necrosis. Green arrow: focal necrosis. Blue arrow: Portal inﬂammation.
and 1000 mg/kg) improved animals’ locomotor activity in the open-
ﬁeld test (Fig. 1). The correlation analysis of taurine-treated groups
was as follows: APAP + Taurine 500 mg/kg; r = −0.653; p < 0.16;
APAP + Taurine 1000 mg/kg; r = −0.936; p < 0.0061; TAA+ Taurine
500 mg/kg; r = −0.492, p < 0.322; TAA+ Taurine 1000 mg/kg; r = -
0.984, p < 0.0004; BDL + Taurine 500 mg/kg; r = −0.982, p < 0.0005;
BDL + Taurine 1000 mg/kg; r = −0.972, p < 0.0012 (Fig. 1).
3.3. Effect of taurine on liver histopathology
Liver histopathological changes in BDL rats revealed as exten-
sive conﬂuent and focal necrosis, inﬂammation and ﬁbrotic changes
of tissue as assessed by hematoxylin & eosin (Fig. 2 upper row
and Table 2) and Masson’s trichrome staining (Fig. 2 lower
row and Table 2). Liver necrosis, inﬂammation, and ﬁbrogenesis
were signiﬁcantly inhibited in BDL rats when they were treated
with TA (500 and 1000 mg/kg live weight) (Fig. 2) (Table 2).
Liver histopathological lesions in thioacetamide-treated animals
involved ballooning degeneration, fatty changes, tissue necrosis
and inﬂammation (Fig. 3) (Table 2). TA administration effec-
tively alleviated thioacetamide-induced histopathological changes
(Fig. 3) (Table 2). A large amount of conﬂuent and focal necrosis
of liver tissue in addition of hemorrhage was detected in the liver
of acetaminophen-treated animals (Fig. 4) (Table 2). TA (500 and
1000 mg/kg live weight, i.p) signiﬁcantly blunted acetaminophen-
induced hepatic injury (Fig. 4) (Table 2) and no sign of liver
necrosis was detected when acetaminophen-intoxicated animals
were treated with TA (Fig. 4) (Table 2).
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Fig. 3. The effect of taurine administration on liver histopathological changes
in  thioacetamide-treated rats (See also Table 2 for grading of tissue histopatho-
logical changes). Representative photomicrographs of liver sections processed
for  H&E staining (400×). Scale bar, 530 m.  A: Control. B: Thioacetamide-
treated rats. C: Thioacetamide + Taurine 500 mg/kg D: Thioacetamide + Taurine
1000 mg/kg. Signs of hepatocytes apoptosis (red arrow), fatty changes and bal-
looning degeneration (black arrow), inﬂammation (yellow arrow), developed in
thioacetamide-administered animals (B) (Table 2). Taurine administration signif-
icantly alleviated thioacetamide-induced lesions (C & D) and no tissue necrosis was
observed in taurine-treated (1000 mg/kg, i.p) animals (D) (Table 2).
Fig. 4. Liver histopathology of acetaminophen-treated mice. Acetaminophen (1000
mg/kg, i.p.) was  administered to mice and animals were sacriﬁced 24 h after
drug treatment. Liver sections were subjected to hematoxylin-eosin (H&E) stain-
ing  (200 × ). Scale bar, 1060 m.  A: represents normal mice liver histopathology.
B:  Acetaminophen-challenged group. C: Acetaminophen + Taurine 500 mg/kg and
D:  Acetaminophen + Taurine 1000 mg/kg. Congestion (Orange arrow), tissue focal
(
t
w
3
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i
Fig. 5. Effect of taurine administration on CYP2E1 activity in liver. TAA: Thioac-
etamide, BDL: Bile duct ligated, APAP: Acetyl para-amino phenol, Acetaminophen.
Data are expressed as Mean ± SEM for each group (n = 6).
**Indicates signiﬁcantly different as compared with control group (P < 0.01).green arrow) and conﬂuent necrosis (red arrow) were detected in acetaminophen-
reated animals (B) (Table 2). No sign of liver necrosis was  detected when taurine
as  administered to acetaminophen-intoxicated mice (C&D) (Table 2).
.4. CYP2E1 inhibitory activity of taurineIt has been reported that taurine affects CYP2E1 enzyme [53].
ence, we assessed the enzyme inhibitory potential of TA in our
xperimental models. We  found that TA administration resulted
n a signiﬁcant decrease in p-nitrophenol metabolizing activity***  Indicates signiﬁcantly different as compared with control group (P < 0.001).
****  Indicates signiﬁcantly different as compared with control group (P < 0.0001).
ns:  not signiﬁcant as compared to the control group.
of CYP2E1 (Fig. 5), which indicates that this amino acid has an
inhibitory effect on CYP2E1 activity in the liver (Fig. 5). BDL, APAP
and thioacetamide did not affect CYP2E1 activity (Fig. 5). Moreover,
there was no signiﬁcant difference in CYP2E1 enzyme inhibitory
effect of administered doses of taurine (500 and 1000 mf/kg)
(Fig. 5).
Finally, it should be mentioned that TA administration (500 and
1000 mg/kg) did not disturb any investigated parameters and ani-
mals showed no signiﬁcant difference with control ones when they
were treated with the sole TA at the mentioned doses.
4. Discussion
In spite of a good body of literature addressing the hepatopro-
tective properties of TA [16], no studies have been conducted on
the effects of this amino acid on blood and brain ammonia, brain
damage and neurological disorders ensued acute and chronic liver
injury. The current investigation was designed to evaluate the role
of TA administration on plasma and brain ammonia as the key
factor associated with hepatic encephalopathy and its consequent
neurological disorders.
Based on previous research, TA provides its protective prop-
erties through different mechanisms, including osmoregulation,
anti-oxidation, membrane stabilization, xenobiotic detoxiﬁcation,
inhibition of ﬁbrogenesis, enzyme inhibition, mitochondrial pro-
tection, anti-apoptosis, modulation of bile acids conjugation, and
anti-inﬂammation [11,13,15,16,55–57].
It has been shown that TA is a potent stellate cells inhibitor
[55,58]. Stellate cells have a great role in collagen formation during
liver ﬁbrosis process (Fig. 6) [59]. The anti-ﬁbrotic properties of TA
have been shown in different other models of liver injury [55,58].
We found that TA (500 and 1000 mg/kg live weight) administra-
tion to bile duct ligated rats, effectively ameliorated liver ﬁbrosis
(Table 2; Ishak grade of liver ﬁbrosis & Fig. 2, lower row). Hence, the
anti-ﬁbrotic properties of TA in BDL model might prevent liver fail-
ure and its consequent deleterious effects such as increase in blood
and brain ammonia and ﬁnally tissue damage. On the other hand,
bile acid conjugating and antioxidant properties of this amino acid
might also play a role in its protective properties against toxic bile
acids accumulated in the liver (Fig. 6).
It has been reported that TA is also a good mitochondrial protec-
tive agent [15,56,57,60]. Toxic bile acids interact with hepatocytes
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Fig. 6. The schematic diagram of the previously reported proposed mechanisms of hepatoprotection provided by taurine in chronic liver injury and cirrhosis.
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pFig. 7. The descriptive hepatoprotective mechanisms of taurine in exitochondrial function (Fig. 6) [61]. Hence, a part of TA hepato-
rotective properties in BDL animals might be attributed to its
rotective properties against mitochondrial dysfunction in the liverental models of acute liver injury. NAPQI: N-acetyl p-quinone imine.(Fig. 6) [15,62,63]. We  also evaluated the role of TA administra-
tion against ammonia-induced mitochondrial dysfunction in an
in vitro model (Unpublished data). We  found that, TA signiﬁcantly
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Unpublished data).
The situation in acute liver injury models and hepatic fail-
re is somewhat different. We  found that TA effectively inhibited
cetaminophen and thioacetamide-induced liver injury. These
ffects have also been reported previously [8,9,64]. Abbasog˘lu
t al. reported that TA administration effectively prevented
hioacetamide-induced chronic liver injury [9]. We  found that
A administration not only effectively inhibited thioacetamide-
nduced acute liver failure, but also it has a great effect on plasma
nd brain ammonia, and neurological disorders associated with
hioacetamide-induced liver failure (Table 1, Fig. 1). As men-
ioned, the effect of TA on acetaminophen-induced liver injury
as also been proved in different experimental models [8,64].
n the current investigation, we found that TA effectively allevi-
ted ammonia-induced complications in acetaminophen-treated
nimals. The antioxidative (Table 1), and more importantly the
nzyme-inhibitory properties of TA (Fig. 5 and Fig. 7), might
e important factors in TA hepatoprotective properties against
cetaminophen or thioacetamide-induced liver injury. It has been
hown that TA is a CYP2E1 inhibitor [53]. TA might inhibit
hioacetamide and acetaminophen bioactivation through CYP2E1
nhibition and consequently prevent liver failure (Fig. 5 and Fig. 7).
oreover, oxidative stress has also been regarded as a major
ontributor to the development of various hepatic disorders includ-
ng xenobiotics-induced acute hepatic failure and hepatic ﬁbrosis
8,65]. Hence, the antioxidant properties of TA [66,67], might also
ave a role in its protective effect against acute liver injury as this
mino acid effectively prevented lipid peroxidation and hepatic
lutathione depletion (Fig. 7). Das et al. have been reported that
A might enhance the urinary excretion of acetaminophen [68].
ence, other mechanisms such as enhancement of excretion of the
epatotoxic agents might also be involved in TA hepatoprotective
roperties.
It has been shown that TA has several important roles in CNS
69]. Effects of this amino acid on CNS disorders also has been
evealed [17]. Moreover, it has been shown that TA has protective
roperties against neurotoxins [70,71]. As mentioned, ammonia
s a neurotoxic agent and many consequences of hyper ammo-
ia on the CNS have been previously described [26,72,73]. It has
een found that elevated brain ammonia caused oxidative stress,
ioenergetic failure, alterations in pH and Ca2+ homeostasis, and
lectrophysiological disturbances in CNS [26,72,73]. The antioxida-
ive, mitochondrial protecting and calcium sequestering effects of
A might be involved in its protective properties against chronic
nd acute liver injury-induced hyperammonemia and its conse-
uent brain injury.
The administered TA doses were chosen based on previous stud-
es [74,75]. We  found no signiﬁcant differences between the effects
f administered TA doses (500 mg/kg and 1000 mg/kg) in most
arameters assessed in the current investigation. This might be due
o the pharmacokinetic parameters. TA transport through blood
rain barrier and issues such as its saturation in different organs
76,77] might contribute in the same effects of different high doses
f TA (500 and 1000 mg/kg) in this study. As both doses of TA
ad signiﬁcant effects on liver and brain we might be able to sug-
est lower doses of TA for future investigations to prevent adverse
vents, if any, associated with this amino acid.
Brain edema is a common ﬁnding in patients with acute/chronic
iver injury [24]. TA effectively lowered ammonia levels and atten-
ated brain edema (%brain water) in our investigation (Table 1).
oreover, TA administration effectively mitigated the decrease in
otor activities associated with chronic and acute liver injury.
nterestingly, it has been shown that TA has inhibitory effects on
strocytes swelling [78]. Astrocytes are the major cells involvedports 3 (2016) 870–879 877
in hyperammonemia-induced brain edema [73]. It has been men-
tioned that brain edema might play a role in the neurologic
complications of hyperammonemia [48,79].
Although it was  not statistically signiﬁcant, brain edema (%brain
water) was tended to rise in thioacetamide-treated animals
(Table 1). Applying other more precise methods of edema assess-
ment such as gradient protocol might provide different results [80].
The percent of brain water (edema) was  signiﬁcantly higher in BDL
rats and APAP-treated animals (Table 1). We found that TA adminis-
tration effectively mitigated brain edema in different experimental
models of HE and hyperammonemia (Table 1, Fig. 7). The effect
of TA on brain astrocytes might be involved in the mechanism by
which this amino acid prevents brain edema in in vivo conditions.
Several studies indicated the occurrence of brain edema in humans
[81], and different animal models of acute and chronic liver injury
[47,82,83]. On the other hand, some investigations mentioned the
predominant role of neuroinﬂammation rather than brain edema
in the pathogenesis of CNS injury in HE [84]. Neuroinﬂammation
is one of the key factors in HE development and ammonia tox-
icity [28,29]. As TA and its derivatives act as anti-inﬂammatory
agents [85–87], one of the interesting mechanisms of neuroprotec-
tive properties of TA against hyperammonemia might be mediated
by this pathway. Further investigations are needed to reveal the
precise effect of TA on neuroinﬂammation in hyperammonemia.
It has been reported that in both acute and chronic liver fail-
ure, brain taurine concentrations are decreased [88]. TA plays an
important role in the osmoregulation and ion (K+ and Ca2+) homeo-
stasis in CNS [88,89]. As the imbalance in CNS ions might lead to
neuro-excitation and complications such as seizure [88], one of
the important beneﬁts of TA in preventing ammonia-induced brain
injury might be mediated through CNS osmoregulation [88].
Indeed, the effect of TA on oxidative stress biomarkers and
antioxidant enzymes along with other more precise techniques
including immunohistochemical staining for detecting astrocytes
swelling and brain inﬂammation [28,80], will provide a more clear
idea on the effect of TA on the brain in hyperammonemia and
hepatic encephalopathy. Moreover, methods which exactly eval-
uate the pathological changes in the speciﬁc regions of the brain
(e.g., stereologic methods which imply a detailed study of neuronal
and glial changes in the brain) will clearly provide more informa-
tion about brain injury induced by ammonia in HE and clear the
mechanisms of neuroprotection provided by TA.
Effect of TA on the mitochondrial injury, bioenergetic and brain
oxidative stress in hyperammonemia, as well as the effect of TA
administration on the urea cycle enzymes in the liver has not been
investigated so far. Effect of this amino acid on these enzymes might
shed light on the mechanism of TA in decreasing plasma ammo-
nia level and provide potential therapeutic options, especially in
chronic liver injury and cirrhosis.
5. Conclusion
The current investigation focuses on the role of TA administra-
tion on the blood and brain ammonia level. Our data indicate that
TA might be a useful agent to preserve liver function and prevent
rise in blood and brain ammonia as a deleterious consequent of
acute and chronic liver injury. Hence, TA supplementation might
be considered as a therapeutic approach to ameliorate the severity
of hepatic impairment and ﬁbrosis in addition of brain damage and
neurological disorders in acute and chronic cases of liver injury.
Furthermore, more investigations on the effect of TA on cerebral
energy metabolism and brain mitochondrial dysfunction will help
to clear the mechanism(s) of its protection against hyperammone-
mia  conditions.
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